Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Modi, Shanu; Jacot, William; Yamashita, Toshinari; Sohn, Joohyuk; Vidal, María; Tokunaga, Eriko; Tsurutani, Junji; T. Ueno, Naoto; Prat, Aleix; Soo Chae, Yee; Seok Lee, Keun; Niikura, Naoki; Hee Park, Yeon; Xu, Binghe; Wang, Xiaojia; Gil‐Gil, Miguel; Li, Wěi; Pierga, Jean‐Yves; Im, Seock‐Ah; C. F. Moore, Halle; S. Rugo, Hope; Yerushalmi, Rinat; Zagouri, Flora; Gombos, Andrea; Kim, Sung‐Bae; Liu, Qiang; Luo, Ting; Saura, Cristina; Schmid, Peter; Sun, Tao; Gambhire, Dhiraj; Yung, Lotus; Wang, Yibin; Singh, Jasmeet; Vitazka, Patrik; Meinhardt, Gerold; Harbeck, Nadia; Cameron, David

doi:10.1056/nejmoa2203690

Public

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Published in New England Journal of Medicine • Jun 5, 2022

Authors:

Shanu Modi

William Jacot

Toshinari Yamashita

Abstract

BACKGROUND: Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" c...

Subject

Trastuzumab

Breast cancer

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!